Despite their own cost concerns, patient groups also express misgivings about standardized drug regimens and flat payments, fearing they may encourage providers “to make treatment decisions based on cost and less on the evidence,” Rosen said.
Yabroff, the epidemiologist at the National Cancer Institute, said concerns about quality are real, and make additional research imperative so that both “quality and cost are evaluated.”
Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation.
Fri, Jun 06 2014